Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, commercial and real world insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share diverse insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health is powered by an authentic, inclusive and high-performance culture that cares for colleagues, customers, patients, communities and the environment.
我們正在追蹤 Syneos Health 的市場擴張
全新 市場推廣與公關 活動 — 剛出現 17 個新訊號。
Syneos Health 的國際擴張與競爭對手的比較
Syneos Health你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Syneos Health你 | 0 | 0 | — | 0 | 0 |
Bus Proc & Perf Analyst
查看招聘Buenos Aires, Buenos Aires Province, Argentina · 前日
L&D Trainer
查看招聘Buenos Aires, Buenos Aires Province, Argentina · 前日
Clinical Support Specialist
查看招聘Buenos Aires, Buenos Aires Province, Argentina · 前日
Incretins. CKM therapies. Combination treatments. Cardiometabolic innovation is advancing rapidly—but complexity is growing just as fast.Discover how our cross-therapeutic model helps sponsors accelerate development in cardiovascular, metabolic and renal programs with greater clarity and speed to market. ...
已結束
The future of cardiometabolic drug development depends on seeing the full picture.Risk doesn't develop in silos and neither should our development strategies.As we head into ADA 2026, I share perspectives on why approaching cardiometabolic disease as an interconnected continuum may help reshape how we think about trial design, risk management and long-term patient outcomes.Read more: Rethinking Risk, Improving Outcomes in Cardiometabolic Drug Development https://lnkd.in/ePUtrRs3If you will be at ...
已結束
Two incredible days of conversations recorded live from the Syneos Health Early Signals podcast booth on the ASCO conference floor 🎙️Over the past 48 hours, I’ve had the opportunity to sit down with leaders across oncology, precision medicine, cell therapy and drug development to discuss the innovations, challenges and breakthroughs shaping what comes next for patients.These are just some of the conversations from the last two days at ASCO, and I’m incredibly grateful to Diana Chen, Nick Glover ...
已結束Veeva Systems的Vault EDC已支持超過1000項試驗，20大生物製藥公司中8家採用，提高臨床數據管理效率。
Telix Pharmaceuticals任命David Gill為非執行董事,於2026年5月11日生效,計劃讓他擔任主席。Gill擁有超過35年生命科學經驗。
Crossject與Syneos Health合作在美國推出ZEPIZURE，這是一種使用無針自動注射器技術的緊急癲癇治療方法。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Syneos Health 業務、市場及增長訊號的快速解答。
